News | Heart Failure | March 05, 2020

Abbott’s In-Development Fully Implantable Heart Pump System Earns FDA’s Breakthrough Device Designation


March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Fully Implantable Left Ventricular Assist System (FILVAS) currently in development. 

The FDA launched the Breakthrough Devices Program in 2018 to help expedite the development and review of submissions for technology that offers significant advantages over existing approved products.

Approximately 6.2 million people in the U.S. are living with heart failure. Because this is a progressive disease, more than 600,000 people each year reach an advanced stage where traditional therapies, such as medication and cardiac resynchronization therapies, no longer work.

“As the leader in heart failure management, a fully implantable heart pump has been our vision for the tens of thousands of people who progress into advanced heart failure each year,” said Michael Pederson, senior vice president for Abbott’s electrophysiology and heart failure division. “The potential for a fully implantable system would mean more freedom and a greater quality of life because there are no external components to be carried everywhere. These advances underscore Abbott’s long-standing commitment to develop innovative devices that allow those with heart failure to live their best lives.”

Heart pumps are small, implantable mechanical devices that pump blood throughout the body in people living with advanced heart failure. Those living with a heart pump are either waiting for a heart transplant or are not candidates for a heart transplant, and need the life-saving device to pump blood from their heart to the rest of their body. Currently, left ventricular assist devices are implanted into the body and then powered using an external battery pack or charging port.

Abbott’s FILVAS is in research and development and is not available for sale anywhere in the world. 


Related Content

News | Heart Failure

March 28, 2023 — People exposed to low doses of ionizing radiation have an extra, but modest, risk of developing heart ...

Home March 28, 2023
Home
News | Heart Failure

March 24, 2023 — Abbott announced new data that found monitoring patients remotely with hemodynamic pressure sensing ...

Home March 24, 2023
Home
News | Heart Failure

March 21, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and ...

Home March 21, 2023
Home
News | Heart Failure

March 21, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and ...

Home March 21, 2023
Home
News | Heart Failure

March 5, 2023 — Doctors who received customized electronic health record (EHR) alerts for specific patients were 2.5 ...

Home March 05, 2023
Home
News | Heart Failure

March 4, 2023 - Lexicon Pharmaceuticals, Inc. announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes ...

Home March 04, 2023
Home
News | Heart Failure

March 3, 2023 — Researchers may be able to predict cardiovascular disease – such as atrial fibrillation and heart ...

Home March 03, 2023
Home
News | Heart Failure

February 24, 2023 — Abiomed, Inc., part of Johnson & Johnson MedTech[1], announced that results from a study on Impella ...

Home February 24, 2023
Home
News | Heart Failure

February 23, 2023 — Lexicon Pharmaceuticals, Inc. announced the upcoming presentation of new analyses of results from ...

Home February 23, 2023
Home
News | Heart Failure

February 22, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and ...

Home February 22, 2023
Home
Subscribe Now